NCT04848064 2026-02-10
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
Clinical Trials
8 trialsNCT05414500 2025-08-08
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
Phase 1 Recruiting
NCT02358473 2024-09-19
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT02867007 2024-04-25
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT04185220 2023-01-04
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02946671 2020-03-06
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
Phase 1 Completed
NCT02444793 2019-02-27
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT01929486 2016-02-17
Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.
Aichi Medical University
Phase 1 Unknown